Press

2013-02-22

Full Year Report 2012 for Kancera AB (publ) January 1 – December 31, 2012

All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m that arose in connection with the...

Read More
2012-11-22

Interim Report for Kancera AB (publ) Q3 2012

All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m that arose in connection with the...

Read More
2012-11-14

Kancera strengthens the evidence that pancreatic cancer is dependent on ROR

Kancera reports results from a collaboration with Professor Håkan Mellstedts research group at Karolinska Institute showing that the survival of an aggressive type of human cancer cells from pancreatic cancer is ROR-1 dependent. The results provide further support for...

Read More
2012-11-06

Kancera reports inhibitory effects on pancreatic cancer in animal studies

Kancera reports that the company's first generation of PFKFB3 inhibiting compounds reduces growth of pancreatic cancer in a pre-clinical animal study.

Read More
2012-10-04

Intellect Neurosciences and iNovacia Enter into a Research Service Agreement

NEW YORK and STOCKHOLM, Oct. 04, 2012 - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and iNovacia, a subsidiary to Kancera AB ...

Read More
2012-08-23

Interim Report for Kancera AB (publ) Q2 2012

All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m that arose in connection with the...

Read More
2012-07-02

Kancera strengthens patent rights related to ROR antibody therapy

Kancera announces that it has signed an agreement with Bioinvent to acquire BioInvent ́s rights to the patent application WO 2011/079902, covering therapeutic antibodies directed against the ROR receptor for treatment of cancer.

Read More
2012-06-13

Kancera to present at the 2012 BIO International Convention

Kancera AB today announced that Dr. Thomas Olin, CEO of Kancera, will present the company at the 2012 BIO International Convention taking place June 18-21 in Boston, USA.

Read More
2012-05-30

Professor Carl-Henrik Heldin strengthens the Board of Kancera

Kancera announces that Professor Carl-Henrik Heldin has been elected to Kancera ́s Board at the company's annual general meeting May 28.

Read More
2012-05-24

Interim Report for Kancera AB (publ) Q1 2012

January 1 - March 31, 2012 All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m...

Read More